0.35
0.35 (0%)
As of Apr 17, 2025
Mersana Therapeutics, Inc. [MRSN]
Source:
Company Overview
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates, or ADCs, that offer a clinically meaningful benefit for cancer patients with significant unmet need. We have leveraged decades of industry learnings to develop two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen.
| Country | United States |
| Headquarters | cambridge, massachusetts |
| Phone Number | (617) 498-0020 |
| Industry | manufacturing |
| CEO | Martin Huber |
| Website | www.mersana.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $40.5 |
| Operating Profit | |
| Net Income | $-69.2 |
| Net Cash | $-66.8 |
Profit Ratios
| Gross Margin | $40.5 |
| Operating Margin | |
| Profit as % of Revenues | -58.5% |
| Profit as % of Assets | -37.3% |
| Profit as % of Stockholder Equity | 727.7% |
Management Effectiveness
| Return on Equity | 727.7% |
| Return on Assets | -47.8% |
| Turnover Ratio | 21.9% |
| EBITA |
Balance Sheet and Cash Flow Measures
| Total Assets | $144.7 |
| Total Liabilities | $154.2 |
| Operating Cash Flow | $-82.3 |
| Investing Cash Flow | $11.4 |
| Financing Cash Flow | $4.1 |
